Tuberculosis treatment outcome in the European  Union and European Economic Area: an analysis of  surveillance data from 2002‒2011 by Karo, Basel et al.
1www.eurosurveillance.org
Research article
Tuberculosis treatment outcome in the European 
Union and European Economic Area: an analysis of 
surveillance data from 2002‒2011
B Karo 1 2 , B Hauer 1 , V Hollo 3 , MJ van der Werf 3 , L Fiebig 1 , W Haas 1 
1. Department for Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany
2. PhD Programme Epidemiology, Braunschweig-Hannover, Germany
3. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Correspondence: Basel Karo (karob@rki.de)
Citation style for this article: 
Karo B, Hauer B, Hollo V, van der Werf M, Fiebig L, Haas W. Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of 
surveillance data from 2002‒2011. Euro Surveill. 2015;20(49):pii=30087. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.49.30087 
Article submitted on 03 February 2015 / accepted on 24 July 2015 / published on 10 December 2015
Monitoring the treatment outcome (TO) of tubercu-
losis (TB) is essential to evaluate the effectiveness 
of the intervention and to identify potential barriers 
for TB control. The global target is to reach a treat-
ment success rate (TSR) of at least 85%. We aimed to 
assess the TB TO in the European Union and European 
Economic Area (EU/EEA) between 2002 and 2011, and 
to identify factors associated with unsuccessful treat-
ment. Only 18 countries reported information on TO for 
the whole observation period accounting for 250,854 
new culture-confirmed pulmonary TB cases. The 85% 
target of TSR was not reached in any year between 
2002 and 2011 and was on average 78%. The TSR 
for multidrug-resistant (MDR)-TB cases at 24-month 
follow-up was 49%. In the multivariable regression 
model, unsuccessful treatment was significantly asso-
ciated with increasing age (odds ratio (OR) = 1.02 per a 
one-year increase, 95% confidence interval (CI): 1.02–
1.02), MDR-TB (OR = 8.7, 95% CI: 5.09–14.97), male 
sex (OR = 1.40, 95% CI: 1.28–1.52), and foreign origin 
(OR = 1.32, 95% CI: 1.03–1.70). The data highlight that 
special efforts are required for patients with MDR-TB 
and the elderly aged ≥65 years, who have particularly 
low TSR. To allow for valid monitoring at EU level all 
countries should aim to report TO for all TB cases.
Introduction
In 1991, the 44th World Health Assembly set targets 
to detect at least 70% of new tuberculosis (TB) cases 
and to cure at least 85% of those detected [1]. The Stop 
TB Partnership developed the Global Plan to Stop TB 
2006–2015 to achieve these targets set for 2015 within 
the context of the Millennium Development Goals [2]. 
Monitoring the outcome of TB treatment is essential to 
evaluate the effectiveness of the intervention and to 
identify the potential barriers for TB control.
In Europe, a Working Group of the World Health 
Organization (WHO) and the International Union 
against Tuberculosis and Lung Disease (IUATLD) pub-
lished recommendations for uniform reporting by TB 
surveillance and cohort analysis of treatment outcome 
(TO) across Europe [3,4]. A minimal set of six exclu-
sive categories of TO was recommended as standard: 
cured, completed, failed, died, interrupted (defaulted) 
and transferred out. Furthermore, analysis of TO 
should be separate for new and retreatment cases [4]. 
In 2008, the European Centre for Disease Prevention 
and Control (ECDC) published the Framework Action 
Plan to fight Tuberculosis in the European Union fol-
lowing the WHO/IUATLD recommendations; including a 
core indicator of 85% treatment success rate for new 
pulmonary culture-confirmed TB cases and 70% for 
new pulmonary culture-confirmed multidrug-resistant 
(MDR) TB cases [5].
In 2013, in the European Union and European Economic 
Area (EU/EEA), the TB notification rate was 12.7 per 
100,000 population [6]. Notification rates were hetero-
geneous: five countries had incidence rates ≥ 20 and 24 
countries had incidence rates < 20 cases per 100,000 
population in 2013) [6]. In the majority of countries 
the trend in case notification rate showed a sustained 
decline during the period 2009-2013. In 2013, the over-
all treatment success rate was 73.5%. 
In this study, we aimed to assess the TB TO in the EU/
EEA and to identify factors associated with unsuccess-
ful treatment applying the WHO/IUATLD recommenda-





Since January 2008, all EU countries (27; since February 
2015 28 countries, after Croatia has joined) and the 
EEA countries Iceland and Norway (Liechtenstein 
has not reported data since 2007) report their avail-
able data on TB to The European Surveillance System 
(TESSy) hosted by ECDC [6]. For years between 1996 
and 2007, data were transferred into TESSy from the 
historical database of the former EuroTB project for the 
TB surveillance activities in Europe. In this paper, we 
analysed data of TB TO during 2002-2011 and extracted 
from TESSy on 2 October 2013.
Since the reporting year 2002, case-based TO data 
have been provided by EU/EEA countries for cases 
notified one year before the year of TO reporting. Since 
2005, TO data of MDR-TB cases have been reported for 
cases notified two years earlier [6]. Thus, for TO analy-
sis of MDR-TB cases data reported between 2005 and 
2010 were used in this study.
Definitions
In line with the WHO/IUATLD recommendation for 
EU/EEA countries [3,4] the cohort eligible for the TO 
analysis included new culture-confirmed pulmonary 
TB cases. Cases are observed until the first outcome 
up to a maximum of 12 months after the start of treat-
ment and MDR-TB cases for 24 months. TO was catego-
rised based on the WHO/IUATLD recommendations [4] 
with two additional categories ‘Still on treatment’ and 
‘Unknown’ (Table 1) [6,7].
A new TB case was defined as a case that never previ-
ously received drug treatment for active TB, or received 
anti-TB drugs for less than one month. Five countries 
(Belgium, Denmark, Ireland, Norway and the United 
Kingdom (UK)) did not report information about previ-
ous treatment and for those previous diagnosis was 
used as a proxy for defining new and previously treated 
cases. 
The term native case refers to cases born in or, if this 
information was unavailable, having citizenship in the 
reporting country. Foreign origin refers to cases born 
in (or citizens of) a country different from the reporting 
country. 
MDR-TB was defined as TB with resistance to at least 
rifampicin and isoniazid. A low TB incidence coun-
try was defined as country with TB incidence rate < 20 
cases per 100,000 population and a high TB incidence 
country with TB incidence rate ≥ 20 cases per 100,000 
population.
Statistical analysis
Data were described by totals and percentages. The 
chi-squared test was used to assess differences 
in categorical variables. Only cases from countries 
Figure 1
Algorithm for inclusion of cases in the analysis on 
treatment outcome of new culture-confirmed pulmonary 
tuberculosis, EU/EEA, 2002–2011 (n=589,688) Algorithm 
for inclusion of cases in the analysis on treatment outcome 
of new culture-confirmed pulmonary tuberculosis, EU/
EEA, 2002–2011 (n=589,688)
810,707 TB cases reported to 
TESSy between 2002 and 2011
705,603 TB cases from countries 
with reportedtreatment outcome 
589,688 TB cases from 18 countries 
that reported treatment outcome for 
the whole study period (2002-2011)*
329,285 culture-confirmed 
pulmonary TB cases
250,854 new culture-confirmed 
pulmonary TB cases eligible for 
treatment outcome analysis†
471,117 pulmonary TB cases 
105,104 TB cases from countries (France, 
Greece, Italy, Liechtenstein and 
Luxembourg) that did not report treatment 
outcome 
115,915 TB cases from countries (Bulgaria, 
Cyprus, Spain, Finland, Lithuania, Portugal 
and Sweden) that did not report treatment 
outcome for the whole study period
118,571 extrapulmonary TB cases 
or cases with no information on TB site
141,832 TB cases with negative culture 
or no information
78,431 TB cases previously treated or 
without information on previous treatment
EEA: European Economic Area; EU: European Union
a Including Austria, Belgium, Czech Republic, Denmark, Estonia, 
Germany, Hungary, Ireland, Iceland, Latvia, Malta, the 
Netherlands, Norway, Poland, Romania, Slovenia, Slovakia and 
the United Kingdom.
b Denmark did not report information on previous treatment in 
2005. These cases were coded as missing in the cohort (n = 428).
Source: The European Surveillance System (TESSy). TESSy was 
operational since 2008 and for data from 2002-2007 data were 
transferred into TESSy from the historical database of the former 
EuroTB project for the TB surveillance activities in Europe.
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that reported on TO for the whole study period were 
included in TO calculation and the statistical model.
Trend analysis of treatment success rate was conducted 
using the nonparametric test for trend across ordered 
groups i.e. the reporting years. A logistic regression 
model was used to examine the association between 
the TO, successful vs unsuccessful, and potential pre-
dictor variables age, sex, geographical origin, MDR-TB 
and reporting year. In the regression model, TB TO 
was categorised as treatment success vs unsuccessful 
treatment. Independent variables were systematically 
investigated in the univariate analysis and in the mul-
tivariable model for adjusting to possible confound-
ers. To correct for the clustering within countries, we 
specified that the standard errors allow for intragroup 
correlation, assuming that the observations are inde-
pendent across groups (clusters) but not necessarily 
within groups. Based on the regression coefficient of 
the model, odds ratios (OR) with their 95% confidence 
interval (CI) were also calculated to assess the strength 
of association.
All tests were two-sided and considered significant if 
p < 0.05. All analyses were performed using STATA (ver-
sion12, StataCorp, LP, TX, US) software.
Ethical statement
This study was based on national surveillance data 
submitted to ECDC. Therefore, written informed con-
sent from the patients was not required due to the 
anonymous nature of the data.
Results
Treatment outcome reporting
Between 2002 and 2011, a total of 810,707 TB cases 
were notified. Of these, 83.3% (n = 675,627) had infor-
mation on TO. The number of countries, that reported 
information on TO, increased from 21 countries in 2002 
to 25 countries in 2011. Five countries (France, Greece, 
Figure 2
Treatment outcome of new culture-confirmed pulmonary tuberculosis cases in the EU/EEA by A. Reporting years B. 
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Italy, Liechtenstein and Luxembourg) did not report 
on TO in any year between 2002 and 2011. Eighteen 
countries (Austria, Belgium, Czech Republic, Denmark, 
Estonia, Germany, Hungary, Ireland, Iceland, Latvia, 
Malta, the Netherlands, Norway, Poland, Romania, 
Slovenia, Slovakia and the UK) provided information 
on TO for the whole 10-year study period (2002–2011), 
corresponding to 589,688 TB cases (72.7% of all 
reported cases). Of these 589,688 TB cases, 42.5% 
(n = 250,854) were new culture-confirmed pulmonary 
TB cases eligible for our analysis (Figure 1).
Significant differences were observed in the demo-
graphic characteristics between included and excluded 
cases. Compared with the excluded cases, the included 
new culture-confirmed pulmonary TB cases were more 
likely to be men (67.2% vs 63.7%; p < 0.001), of native 
origin (84.4% vs 78.7%; p < 0.001) and non-MDR-TB 
(98.6% vs 97.9%, p < 0.001) respectively. Also, the treat-
ment success rate was higher in included cases com-
pared with excluded ones (78.2% vs 71.1%; p < 0.001).
Cohort characteristics
The majority of cohort cases were reported by Romania, 
Poland, Germany and the UK (45.1%, 17.8%, 9.7% and 
9.5% respectively). The median age of cases was 45 
years (interquartile range (IQR) 31–57). Of cohort cases 
67.2% were male and 14.9% were of foreign origin. 
MDR-TB was reported in 1.4% (n = 3,597) of the cohort 
cases, mainly from Romania (n = 1,219), Latvia (n = 802) 
and Estonia (n = 460). Information of drug susceptibility 
Figure 3
Treatment success rate of new culture-confirmed pulmonary tuberculosis in the EU/EEA. 3A. Age group 3B. Treatment 
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testing results for isoniazid and rifampicin was missing 
in almost half of the cases (48.4%) (Table 2).
Twelve-month treatment outcome
The overall proportion of cases with reported treatment 
success was 78.2% (country range 56.6% in Hungary to 
86.8% in Norway). Treatment success rate was higher 
among female cases compared with male cases (81.6% 
vs 76.5% respectively; p < 0.01) overall and in each 
respective reporting year, age group and geographi-
cal origin (data not shown). About 6.5% of TB cases 
died (country range 2.2% in Malta to 14.4% in Czech 
Republic). On average, 2.4% of cases were still on 
treatment at the end of the 12-month follow-up period 
(country range 0% in Iceland to 13.7% in Estonia); 
32.7% of these cases were MDR-TB. The proportion 
of cases with unsatisfactory outcome 12 months after 
start of treatment was 8.9% (country range 2.0% in 
Iceland and Germany to 19.6% in Hungary). Of them 
2.2% were reported as treatment failure, 5.7% as 
defaulted and 1.0% as transferred out. Cases with 
unknown TO accounted for 4.0% (country range 0% in 
Latvia and Estonia to 17.6% in Ireland) (Figure 2).
The treatment success rate decreased with increasing 
age (85.3% treatment success in cases aged < 15 years 
vs 68.4% in cases aged > 64 years; p < 0.001) (Figure 
3a,b). The death rate rose substantially with increasing 
age of cases (1.8% death rate in cases aged < 15 years 
vs 19.4% in cases aged > 64 years; p < 0.001) (Figure 3b). 
A higher proportion of cases with unknown outcome 
was noticed among cases aged < 15 years compared 
with other age groups.
The treatment success rate was slightly higher among 
native cases than among cases of foreign origin (78.7% 
vs 77.3% respectively; p = 0.05). In native cases, a 
higher proportion of deaths (6.9% in native cases vs 
4.3% in cases of foreign origin; p < 0.001) and treatment 
failure (2.7% in native cases vs 0.2% in cases of for-
eign origin; p < 0.001) was observed. Also the propor-
tion of cases with advanced age was higher in native 
cases than cases of foreign origin (cases aged > 64 
years accounted for 17.2% in native cases vs 10.8% 
in cases of foreign origin; p < 0.001). The proportion 
of cases with unknown outcome was markedly higher 
in cases of foreign origin than in native cases (3.0 vs 
6.5% respectively; p < 0.001).
Adjusting for age and country of origin revealed no 
significant differences in treatment success rate 
between countries with low or high incidence (OR 0.7; 
p = 0.1). Noticeably, the proportion of elderly aged >64 
years was higher in low incidence countries compared 
with high incidence countries (cases aged > 64 years 
accounted for 20.9% vs 14.6% respectively; p < 0.001). 
Similarly, cases of foreign origin were more presented 
in low incidence countries (44.7% vs 0.8% respec-
tively; p < 0.001).
Twenty-four-month treatment outcome of 
multidrug-resistant tuberculosis
Between 2005 and 2010, 2,140 MDR-TB cases were 
reported from the 18 EU/EEA countries included in the 
analysed cohort. The overall treatment success rate for 
MDR-TB cases at 24-month follow-up was 49.2% and 
did not reach the 70% target of treatment success rate 
for MDR-TB cases in any year of the observation period. 
About 12.0% of MDR-TB cases died and 7.3% were still 
on treatment at the end of 24-month follow-up. The 
proportion of cases with unsatisfactory outcome was 
26.3% (including 13.1% failed, 12.4% defaulted and 
0.8% transferred out). About 5.2% of the MDR-TB cases 
were reported with unknown TO (Figure 4).
Trend analysis
The 85% target of overall treatment success rate was 
not reached in any year between 2002 and 2011. 
Analysis of trends shows that the treatment success 
rate increased from 75.4% in 2002 to 79.8% in 2006 
(p = 0.04), then subsequently decreased to 76.6% in 
2011 (p = 0.07). No change in the cohort profile regard-
ing proportions of age groups, sex and MDR-TB was 
observed over time. The proportion of cases of for-
eign origin increased from (N=3672; 14.5%) in 2006 
to (N=4081; 18.5%) in 2011 (p < 0.001). Some countries 
(Belgium, Germany, Hungary, Romania and the UK) 
showed a continuous increase in the treatment success 
rate throughout the observation period, while for other 
countries (Austria, Denmark, Estonia, Netherlands and 
Poland) a decline was observed (data not shown).
Figure 4
Treatment outcome at 24-month follow-up for new 
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transferred into TESSy from the historical database of the former 
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Factors associated with unsuccessful treatment
In the multivariable logistic regression model, unsuc-
cessful treatment was significantly associated with 
increasing age of the case (adjusted OR (aOR) = 1.02 
per a one-year increase, 95%CI: 1.02–1.02), male 
sex (aOR = 1.40, 95%CI: 1.28–1.52) and foreign origin 
(aOR = 1.32, 95%CI: 1.03–1.70). The strongest associa-
tion with unsuccessful treatment was observed with 
MDR-TB (aOR = 8.7, 95%CI: 5.09–14.97). No associa-
tion was found between unsuccessful treatment and 
reporting period (aOR = 0.96, 95%CI: 0.71–1.30) (Table 
3). In a separate analysis using a multivariable multi-
nomial model, we did not find any difference in factors 
associated with death and those associated with the 
other unsuccessful treatment outcomes i.e. unsatisfac-
tory outcome, still on treatment and unknown outcome 
(data not shown).
Discussion
This study investigated TB TO and factors associated 
with unsuccessful treatment in the EU/EEA over 10 
years following the WHO/IUATLD recommendations 
for cohort analysis. It shows that the overall treatment 
success rate of new culture-confirmed pulmonary TB 
cases in the EU/EEA was 78.2% and failed to reach the 
85% target in any year between 2002 and 2011. The 
study also indicates that main factors associated with 
unsuccessful treatment were increasing age, male sex, 
foreign origin and MDR-TB.
Still some countries do not provide information on TO 
to TESSy and for those who reported on TO, the propor-
tion of cases with unknown outcome remained high at 
4.0% overall. It is true that an unknown TO does not 
necessarily represent a negative one, yet from a pro-
grammatic perspective, lack of knowledge about TO 
deprives the programme from important information 
to guide TB control. Moreover, no significant improve-
ment in treatment success rate was observed over the 
10-year study period. These findings demonstrate a 
programmatic weakness within TB control in the EU/
EEA and highlight the urgent need for strengthening 
the monitoring and evaluation process at country level 
[8].
Another analysis of data in TESSy reported by 22 EU/
EEA countries in 2007, showed a treatment success rate 
of 79.5% for new culture-confirmed pulmonary cases 
[8]. A meta-analysis of published reports of TB TO in 
Europe found that 74.4% of outcomes were successful 
[9]. Another study conducted in 18 EU/EEA countries in 
2005, showed a mean success rate of only 69% [10]. 
These results need to be compared with caution due to 
the different definition of cohort used and the different 
study periods [11]. Higher treatment success rates were 
reported in low incidence countries in North America, 
with 89% in the United States (US) in 2013, and with 
86% in 2012 in Canada [12,13].
In the multivariable regression model, male sex was 
independently associated with unsuccessful treatment. 
The lower treatment success rate in men compared 
Categories Definitions 
Cured Treatment completion and culture-negative samples taken at the end of treatment and on at least one previous occasion.
Completed Treatment completed, but case does not meet the criteria to be classified as cured or treatment failure.
Failed Culture or sputum smear remaining positive or becoming positive again five months or later into the course of treatment. 
Died Death before cured or treatment completion, irrespective of cause.
Defaulted Treatment interrupted for two months or more, not resulting from a decision of the care provider. 
Transferred out Patient referred to another clinical unit for treatment and information on outcome not available. 
Still on treatment Patient still on treatment at 12 months and at 24 months for MDR-TB cases without any other outcome during treatment.
Unknown outcome Information on outcome not available, for cases not known to have been transferred. 
Groups created for the purpose of this study 
Unsatisfactory outcome The percentage of cases that interrupted treatment, were transferred or failed treatment out of all notified.
Successful outcome/treatment success The percentage of cases that were cured or completed treatment out of all notified.
Unsuccessful treatment The percentage of cases that were not cured or completed treatment out of all notified (i.e. unsatisfactory outcome, death, still on treatment and unknown outcome). 
ECDC: European Centre for Disease Prevention and Control; IUATLD: International Union against Tuberculosis and Lung Disease; WHO: World 
Health Organization.
Table 1
Summary of tuberculosis treatment outcome categories according to the WHO/IUATLD recommendations and the ECDC 
surveillance report 2015
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with women was mostly attributed to a higher propor-
tion of died, failed and defaulted in men compared 
with women, which persisted when stratifying by 
reporting year, country of origin and age group (with 
exception among cases aged < 15 years). Another study 
done in the EU reported also that the success rate was 
higher in women and this was due to a greater occur-
rence of defaulted and treatment failure in men [10]. A 
study from South Africa found that men were less likely 
to adhere to their treatment than women and male 
sex was associated with the risk of treatment inter-
ruption [14]. The poorer TO in men can be attributed 
to some behavioural components such as alcohol and 
drug abuse, which are still predominant among men. 
Studies done in Paris [15] and Hamburg [16] indicated 
that unsuccessful TB treatment was associated with 
alcohol and injecting drug use. A Spanish study showed 
that injecting drug use was associated with treatment 
default; while alcoholism was associated with death 
during TB treatment [17]. According to the European 
Demographic and clinical 
features of TB cases
Number of cases 






< 15 3,477 1.4
15–44 125,800 50.2
45–64 79,815 31.8
> 64 41,718 16.6
Unknown 44 0.02
Geographical origin 
Native cases 202,129 80.6











Countries with low TB incidence 
rateb 82,711 33.0
Countries with high TB incidence 
ratec 168,143 67.0
Countries reporting treatment outcome for the whole study period 
Austria 4,030 1.6
Belgium 4,922 2.0









The Netherlands 5,205 2.1
Table 2 A*
Characteristics of new pulmonary culture-positive 
tuberculosis cases in the EU/EEAa, 2002–2011 (n=250,854)
EU: European Union; EEA: European Economic Area; TB: 
tuberculosis; UK: United Kingdom.
a Including 18 countries that reported treatment outcome for the 
whole study period: Austria, Belgium, Czech Republic, Denmark, 
Estonia, Germany, Hungary, Ireland, Iceland, Latvia, Malta, the 
Netherlands, Norway, Poland, Romania, Slovenia, Slovakia and 
the United Kingdom.
b Countries with low TB incidence rate (<20,000/100,000 
population) included Austria, Belgium, Czech Republic, 
Denmark, Germany, Hungary, Ireland, Iceland, Malta, the 
Netherlands, Norway, Slovenia, Slovakia and UK.
c Countries with high TB incidence rate (≥20,000/100,000 
population) included Estonia, Latvia, Poland and Romania.
Source: The European Surveillance System (TESSy). TESSy was 
operational since 2008 and for data from 2002-2007 data were 
transferred into TESSy from the historical database of the former 
EuroTB project for the TB surveillance activities in Europe.
Demographic and clinical 
features of TB cases
Number of cases 
(n = 250,854 cases) Percent 








Success (cured or treatment 
completed) 196,105 78.2
Died 16,222 6.5




Transferred out 2,653 1.0
Unknown outcome 9,985 4.0
Table 2 B*
Characteristics of new pulmonary culture-positive 
tuberculosis cases in the EU/EEAa, 2002–2011 (n=250,854)
EU: European Union; EEA: European Economic Area; TB: 
tuberculosis; UK: United Kingdom.
a Including 18 countries that reported treatment outcome for the 
whole study period: Austria, Belgium, Czech Republic, Denmark, 
Estonia, Germany, Hungary, Ireland, Iceland, Latvia, Malta, the 
Netherlands, Norway, Poland, Romania, Slovenia, Slovakia and 
the United Kingdom.
b Countries with low TB incidence rate (<20,000/100,000 
population) included Austria, Belgium, Czech Republic, 
Denmark, Germany, Hungary, Ireland, Iceland, Malta, the 
Netherlands, Norway, Slovenia, Slovakia and UK.
c Countries with high TB incidence rate (≥20,000/100,000 
population) included Estonia, Latvia, Poland and Romania.
Source: The European Surveillance System (TESSy). TESSy was 
operational since 2008 and for data from 2002-2007 data were 
transferred into TESSy from the historical database of the former 
EuroTB project for the TB surveillance activities in Europe.
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Monitoring Centre for Drugs and Drug Addiction, drug 
use and alcohol consumption are considerably more 
common among men than women in EU countries [18]. 
Biological factors may also contribute to the different 
TB TO between males and females. Animal models 
showed that male mice developed more severe TB dis-
ease, while females were more resistant and exhibit 
more robust immune responses to infection [19].
In our study, the proportion of cases with unsatisfac-
tory outcomes was 8.9%; thus below the maximum pro-
portion of 10% in the WHO/IUATLD recommendations. 
This threshold aims to serve National TB Programmes 
as an orientation to direct their efforts in improving 
TO [4]. Three countries: Hungary, Poland and Romania, 
exceeded the 10% proportion of unsatisfactory out-
comes. The proportion of deaths (any cause) was on 
average 6.5%. A high proportion of deaths among pul-
monary TB cases (10%) was also reported by Canada 
in 2012 [13].
An inverse relationship between treatment success 
rate and increasing age was observed in this study. 
This can be partially explained by the increasing death 
rate with advancing age; as a result of demographic 
changes with an ageing population. However, stud-
ies from high- and low-incidence countries reported 
that older age also increases the risk of unsuccessful 
TB treatment [20-22]. The elderly are at increased risk 
for missed diagnosis [23] due to the fact that a diag-
nosis of TB among the elderly is often difficult due to 
atypical, non-specific clinical manifestation and may 
be confused with other concomitant age-related dis-
eases [24,25]. This can lead to a delayed diagnosis and 
more advanced disease at presentation which in turn 
leads to increased mortality among the elderly [24,25]. 
A study in Norway demonstrated that deaths occurred 
mainly because TB diagnosis was established too late 
and half of the cases were only detected at autopsy 
[26]. Also a study from the US found that advanced age 
was strongly associated with unrecognised pulmonary 
TB leading to premature death [27]. Therefore, a high 
index of suspicion for TB in the elderly is undoubtedly 
justifiable [23]. Most recently, the WHO Framework 
towards TB elimination in low-incidence countries high-
lighted the particular challenges in treating active TB 
in the elderly and the importance of early diagnoses 
among them [28]. Furthermore, screening for active 
TB among the elderly has been suggested by WHO 
depending on the local TB epidemiology and risk-ben-
efit assessments [28]. At present in Japan, early case 
detection and treatment are considered as the most 
effective TB control measures among the elderly in 
order to protect them from TB death [29].
In our analysis, MDR-TB was the strongest risk factor 
for unsuccessful treatment and treatment success rate 





Yes No OR (95% CI) p value
AOR 
(95% CI) p value
Increase in age per year 
(continues variable) 196,895 53,959  1.02 (1.01–1.02)  < 0.001 1.02 (1.02–1.02) < 0.001
Sex 




Male 129,323 39,119 1.38 (1.27–1.49) 1.40 (1.28–1.52)
Country of origin 




Cases of foreign origin 29,151 8,320 1.07 (0.74–1.56) 1.32 (1.03–1.70)
Multidrug-resistance 




Yes 1,252 2,345 7.12 (4.07–12.44) 8.7 (5.09–14.97)
Unknown 95,977 25,400 1.00 (0.77–1.32) 0.96 1.08 (0.86–1.36) 0.51
Reporting year 




2007 to 2011 91,329 24,514 0.96 (0.77–1.19) 0.96 (0.71–1.30)
EU: European Union; EEA: European Economic Area; MDR: multidrug-resistant; TB: tuberculosis. 
aUnivariable and multivariable analysis were performed using logistic regression models specifying that standard errors allow for intra-
country correlation (controlling for clustering within countries).
bTuberculosis cases with available information for all predicting factors were included in the multivariable analysis (n = 239,485/250,854).
The logistic regression models were based on 12-month outcomes for non-MDR TB cases and on 24-month outcomes for MDR-TB cases.
Source: The European Surveillance System (TESSy). TESSy was operational since 2008 and for data from 2002-2007 data were transferred into 
TESSy from the historical database of the former EuroTB project for the TB surveillance activities in Europe.
Table 3
Factors associated with treatment outcome among new culture-confirmed pulmonary tuberculosis cases, 2002–2011 
(n=250,854)
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below the 70% target, a sign of the seriousness of the 
MDR-TB epidemic in the EU/EEA. It is well documented 
that treatment failure and mortality are higher among 
MDR-TB cases than among susceptible cases [30,31].
Although we found only a slight difference in treat-
ment success rate in native and foreign cases, being 
of foreign origin was a significant risk factor for unsuc-
cessful TO in our analysis. Markedly, a high proportion 
of cases of foreign origin had unknown outcome. It is 
unclear to which extent this might be due to migration 
for medical reasons. Overall, this result suggests that 
programmatic issues may play a role including access 
to healthcare in the context of mobility e.g. patients 
returning to their country of origin before the treatment 
is completed, as was observed in a study from London 
[32], and challenges in cross-border collaboration. 
Thus, the 61st World Health Assembly in 2008 called 
on countries to address migrant health issues in a more 
integrated, harmonised approach [33]. Foreign origin 
may be a proxy for other unmeasured indicators related 
to migration. In the EU, migrants have been reported to 
be at risk of not receiving the same level of healthcare 
in the preventive, diagnostic and treatment services 
as the native communities [34]. This might be due to a 
combination of factors including legal and working sta-
tus, social exclusion, substandard economic condition 
and barriers in accessing healthcare services [34].
Limitations
This study has a number of limitations. A consider-
able proportion of reported cases was without infor-
mation on TO and was therefore excluded from the 
analysis. Following the WHO/IUATLD recommendation 
for TO monitoring in the EU/EEA, only new culture-
confirmed pulmonary TB cases were eligible for the 
analysis cohort, accounting for 42% of reported cases. 
Furthermore, a higher treatment success rate was 
found among included cases compared to excluded 
ones. Our results thus reflect the situation of the 
defined cohort and might overestimate the overall 
treatment success rate in the EU/EEA. A possible selec-
tion bias related to reporting countries can be noticed; 
some countries were overrepresented in our cohort 
e.g. Romania accounted for 45% of the cases included. 
Information on drug susceptibility testing results was 
missing for almost half of cases, some of whom may 
have been MDR-TB. Due to the unavailability of cause 
of death information in the database, we could not 
distinguish between cases who died from TB or due 
to other causes during TB treatment. This would be 
of particular importance for analysing TO among the 
elderly. With the data currently reported to TESSy, it 
is not possible to investigate some factors known to 
be associated with TB TO such as comorbidity (like HIV 
infection), drug or alcohol abuse, homelessness and 
other socioeconomic factors. These underlying fac-
tors are important for mapping risk groups in order to 
improve TB prevention and access to TB services, since 
TB is concentrated in certain at-risk groups in most low-
incidence countries [28]. Poor implementation of TB 
programme guidelines in some EU/EEA countries might 
partially account for suboptimal TO, especially among 
MDR-TB cases. However, the degree of implementation 
of guidelines within countries and the appropriateness 
of the guidelines are beyond the scope of this paper.
Conclusion
In conclusion, shortcomings in TO reporting remain a 
challenge in monitoring TB control in the EU/EEA. The 
treatment success rate was 78%, below the global tar-
get of 85% for the decade after 2002. Special efforts 
are required for patients with MDR-TB, who have partic-
ularly low treatment success rates. For elderly patients, 
a high index of clinical suspicion for TB is required to 
ensure early diagnosis and treatment of TB [24], and 
improve TO among them. Finally, to allow for valid 
monitoring at EU/EEA level, all countries should aim 
to report TO for all TB cases. Collecting additional vari-
ables on social determinants, alcohol and drug abuse, 
and co-morbidities could increase our understanding 
of the factors related to TB TO and support the design 
of appropriate interventions.
*Erratum
Table 2 had to be replaced due to technical issues on 11 
December 2015.
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